Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Long-term immunosuppression in renal transplant recipients (RTRs) causes various skin manifestations, ranging from cosmetic conditions to severe infections and malignancies.
A cross-sectional descriptive study was conducted at Phramongkutklao Hospital from January 1, 2014, to December 31, 2024, involving 260 RTRs.
The median age of the 260 RTRs was 47 years (range: 18–79). Immunosuppressive regimens included calcineurin inhibitors, azathioprine, mycophenolate mofetil/mycophenolic acid, cyclosporine, and prednisolone. A total of 195 cutaneous manifestations were identified, excluding xerosis and scars. Viral infections (18.1%) were the most common, including herpes zoster (8.8%), herpes simplex (6.5%), and warts (5%). Fungal infections (16.2%) included pityrosporum folliculitis (7.3%), dermatophytes (5.4%), and pheohyphomycosis (0.8%). Drug-induced acneiform eruptions were observed in 11.2%. Herpes zoster occurred at a median of 798 days (range: 32–10,045), with 78.3% of cases occurred after the first year after transplantation. Graft rejection (41.15%) significantly increased herpes zoster prevalence (15.9% vs. 3.9%, p = 0.001). Prednisolone dosages ≥ 20 mg/day correlated with significantly higher prevalence of herpes zoster (30% vs. 8%, p < 0.05), dermatophytes (20% vs. 4.8%, p < 0.05), pityrosporum folliculitis (50% vs. 5.6%, p < 0.001), and acneiform eruptions (50% vs. 5.6%, p < 0.001).
Skin conditions are prevalent in RTRs, particularly after the first-year post-transplant. Associations between graft rejection, high-dose prednisolone, and herpes zoster warrant further study.
